Uwai Yuichi, Taniguchi Risa, Motohashi Hideyuki, Saito Hideyuki, Okuda Masahiro, Inui Ken-ichi
Department of Pharmacy, Kyoto University Hospital, Faculty of Medicine, Kyoto University, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.
Drug Metab Pharmacokinet. 2004 Oct;19(5):369-74. doi: 10.2133/dmpk.19.369.
Human organic anion transporters hOAT1 (SLC22A6) and hOAT3 (SLC22A8) are responsible for renal tubular secretion of an antifolic acid methotrexate, and are considered to be involved in drug interaction of methotrexate with nonsteroidal anti-inflammatory drugs (NSAIDs). In our hospital, a delay of methotrexate elimination was experienced in a patient with Hodgkin's disease, who took loxoprofen, a commonly used NSAID in Japan, which suggested a cause. In this study, we examined the drug interaction via hOAT1 and hOAT3, using Xenopus laevis oocytes. hOAT1 and hOAT3 mediated the methotrexate transport with low affinity (K(m) of 724.0 muM) and high affinity (K(m) of 17.2 muM), respectively. Loxoprofen and its trans-OH metabolite, an active major metabolite, markedly inhibited the methotrexate transport by both transporters. Their inhibition concentrations (IC(50)) were in the range of the therapeutic levels. These findings suggest that loxoprofen retards the elimination of methotrexate, at least in part, by inhibiting hOAT1 and hOAT3.
人类有机阴离子转运体hOAT1(SLC22A6)和hOAT3(SLC22A8)负责肾小管分泌抗叶酸药物甲氨蝶呤,并且被认为参与了甲氨蝶呤与非甾体抗炎药(NSAIDs)的药物相互作用。在我们医院,一名霍奇金病患者在服用日本常用的非甾体抗炎药洛索洛芬后出现甲氨蝶呤清除延迟,这提示了其中的原因。在本研究中,我们使用非洲爪蟾卵母细胞研究了通过hOAT1和hOAT3介导的药物相互作用。hOAT1和hOAT3分别以低亲和力(米氏常数K(m)为724.0 μM)和高亲和力(米氏常数K(m)为17.2 μM)介导甲氨蝶呤转运。洛索洛芬及其反式-OH代谢产物(一种活性主要代谢产物)显著抑制了两种转运体对甲氨蝶呤的转运。它们的抑制浓度(IC(50))处于治疗水平范围内。这些发现表明,洛索洛芬至少部分地通过抑制hOAT1和hOAT3来延缓甲氨蝶呤的清除。